Open Access

Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers

  • Authors:
    • Jie Ling
    • Xianmin Xie
    • Yue Wang
    • Weifang Huang
    • Jun Luo
    • Jingqun Su
    • Hongqiao Fan
    • Shiting Wu
    • Lifang Liu
  • View Affiliations

  • Published online on: June 8, 2022     https://doi.org/10.3892/etm.2022.11427
  • Article Number: 500
  • Copyright: © Ling et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The etiology and pathogenesis of granulomatous lobular mastitis (GLM) remain largely elusive and the expression levels and regulatory roles of microRNAs (miRNAs or miRs) in GLM have remained mostly undetermined. In the present study, the miRNAs that were differentially expressed in breast biopsy samples from patients with GLM and normal tissue adjacent to fibroadenoma were analyzed, a comprehensive differential expression profile of miRNAs was provided and potential biomarkers were screened out. The expression profile of miRNAs was determined by high‑throughput sequencing in the tissues of patients with GLM and healthy controls. Significantly differentially expressed miRNAs were screened by threshold setting and cluster analysis and their target genes were analyzed by Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment. Finally, circulating differentially expressed miRNAs between the GLM and control groups were further analyzed by reverse transcription‑quantitative PCR (RT‑qPCR). A total of 31,077 miRNAs were detected by high‑throughput sequencing. By using the cutoff criteria of |log2 fold change|>2.5 and q<0.001, 13 miRNAs that were indicated to be GLM biomarkers were screened out. The expression levels of these 13 miRNAs in the GLM group were higher than those in the control group. GO and KEGG enrichment analyses suggested that the occurrence and development of GLM may be associated with autoimmune inflammation, metabolism and pathogenic organisms. miR‑451a and miR‑5571‑3p were confirmed to be significantly increased in the serum of patients with GLM compared with their levels in the serum of healthy volunteers, which suggests that they may be used as biomarkers of GLM. To the best of our knowledge, the present study was the first report detailing genome‑wide miRNA profiling of patients with GLM compared with controls. The possible targets and pathways of GLM were evaluated by bioinformatics analysis. The present study identified 13 differentially expressed miRNAs with important theoretical significance and potential application. Furthermore, miR‑451a and miR‑5571‑3p were verified by RT‑qPCR as possible biomarkers of GLM.
View Figures
View References

Related Articles

Journal Cover

August-2022
Volume 24 Issue 2

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ling J, Xie X, Wang Y, Huang W, Luo J, Su J, Fan H, Wu S and Liu L: Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers. Exp Ther Med 24: 500, 2022
APA
Ling, J., Xie, X., Wang, Y., Huang, W., Luo, J., Su, J. ... Liu, L. (2022). Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers. Experimental and Therapeutic Medicine, 24, 500. https://doi.org/10.3892/etm.2022.11427
MLA
Ling, J., Xie, X., Wang, Y., Huang, W., Luo, J., Su, J., Fan, H., Wu, S., Liu, L."Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers". Experimental and Therapeutic Medicine 24.2 (2022): 500.
Chicago
Ling, J., Xie, X., Wang, Y., Huang, W., Luo, J., Su, J., Fan, H., Wu, S., Liu, L."Differential expression profiles of miRNA in granulomatous lobular mastitis and identification of possible biomarkers". Experimental and Therapeutic Medicine 24, no. 2 (2022): 500. https://doi.org/10.3892/etm.2022.11427